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The Bloom’s syndrome protein, BLM, is a member of
the conserved RecQ helicase family. Although cell
lines lacking BLM exist, these exhibit progressive
genomic instability that makes distinguishing
primary from secondary effects of BLM loss prob-
lematic. In order to be able to acutely disable BLM
function in cells, we undertook a high throughput
screen of a chemical compound library for small
molecule inhibitors of BLM. We present ML216,
a potent inhibitor of the DNA unwinding activity of
BLM. ML216 shows cell-based activity and can
induce sister chromatid exchanges, enhance the
toxicity of aphidicolin, and exert antiproliferative
activity in cells expressing BLM, but not those lack-
ing BLM. These data indicate that ML216 shows
strong selectivity for BLM in cultured cells. We
discuss the potential utility of such a BLM-targeting
compound as an anticancer agent.
INTRODUCTION
DNA helicases are ATP-dependent enzymes that separate the
complementary strands of duplex DNA (Soultanas and Wigley,
2001). Several families of helicases have been identified,
including the RecQ helicases, which are conserved between
bacteria, yeasts, and all higher eukaryotes (Bachrati and Hick-
son, 2003). In human cells, there are five RecQ family members,
designated RECQ1, RECQ4, RECQ5, BLM, and WRN, all of
which contain a centrally located domain with seven signature
motifs found in the so-called Superfamily II helicases (Chu and
Hickson, 2009). These motifs include the Walker A and B boxChemistry & Biology 20,sequences required for the binding and hydrolysis of ATP that
drives DNA strand separation. Mutation of any of the three
genes encoding human RecQ proteins (BLM, WRN, and
RECQ4) gives rise to a defined genetic disorder associated
with premature aging and/or cancer predisposition (Chu and
Hickson, 2009). Cells from affected individuals in all cases
show excessive chromosomal instability. One of these condi-
tions, Bloom’s syndrome (BS) is caused by mutation of the
BLM gene, which is located on chromosome 15q26.1 in humans
(Ellis et al., 1995).
BS is characterized by predisposition to the development of
cancer, growth retardation, immunodeficiency, sunlight sensi-
tivity, and fertility defects. Leukemia and lymphoma are the
most commonly observed cancer types, but the full spectrum
of cancers in the normal population is evident in BS (German,
1997). Although the cells from many BS individuals lack ex-
pression of the BLM protein, it is clear that BLM function is
essential for viability in mice, with homozygous deletion of the
gene leading to embryonic lethality by day 13.5 (Chester et al.,
1998). Cells from BS patients exhibit extensive chromosome
instability. This is manifested as increased numbers of chro-
matid gaps and breaks, as well as chromosome structural rear-
rangements, including symmetrical quadriradials, micronuclei,
anaphase bridges, and lagging chromosomes (Chu and Hick-
son, 2009). The characteristic cellular feature, used in themolec-
ular diagnosis of BS, is an increase in the frequency of sister
chromatid exchanges (SCEs) (Chaganti et al., 1974).
BLM protein displays an ATP-dependent, 30-50 DNA helicase
activity that can unwind a variety of DNA substrates that can
arise during DNA replication and repair. These include various
types of partial duplex DNA substrates, which are unwound
in a DNA structure-specific manner (Mohaghegh et al.,
2001). BLM also exhibits an activity that can branch migrate
three- and four-way DNA junctions that model a DNA displace-
ment loop (D-loop) and a Holliday junction recombination55–62, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 55
Figure 1. ML216 Is an Inhibitor of BLM
Activity In Vitro
(A) Structure of MLS000559245 that was identified
during the high-throughput screen and ML216,
which was developed through subsequent medic-
inal chemistry optimization of this chemotype.
(B) Effects on ML216 on the helicase activity of
BLM636-1298 and full-length BLM. In the absence of
ML216, BLM unwinds the forked duplex into
ssDNA (depicted diagrammatically on the right).
The open triangle above the left lane in each case
depicts heat-denatured DNA. The asterisk
denotes fluorescent end label.
(C) Quantification of the extent of BLM inhibition
by ML216. Data represent the average of three
independent experiments. Error bars: SD.
See also Figure S1.
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Inhibitor of BLMintermediate, respectively (Bachrati et al., 2006; van Brabant
et al., 2000). Finally, BLM can disrupt some non-B-form DNAs,
such as G-quadruplexes (Sun et al., 1998). To perform these
functions, BLM associates with conserved partner proteins,
including topoisomerase IIIa and RMI1 and 2 (Brosh et al.,
2000; Chang et al., 2005; Meetei et al., 2003; Singh et al.,
2008; Wu et al., 2000, 2001; Yin et al., 2005).
Although it is possible to study BLM function using BS cell
lines, these cells exhibit ongoing genomic instability making it
difficult to distinguish primary from secondary consequences
of BLM loss. Attempts to overcome this problem have focused
on the use of small interfering RNA (siRNA)/small hairpin RNA
(shRNA)-mediated depletion of BLM, which suffers from an
inability to acutely disable BLM and requires a timescale of
several days to be effective. We reasoned, therefore, that a small
molecule inhibitor of BLM would permit a number of studies to
be undertaken that cannot be conducted with existing cell lines.
Moreover, it was our intention to identify ‘‘molecular probes’’’ of
BLM function that could be used not only to conduct synthetic
lethality type screens in human cells, but also to serve as lead
compounds in the search for potential anticancer agents.
In this study, we report the characterization of a small mole-
cule inhibitor of BLM, identified through high-throughput
screening (HTS) and medicinal chemistry optimization. This
compound, designated ML216, is potent and acts through
competitive inhibition of the DNA binding activity of BLM. In
cell-based assays, ML216 induces SCEs in cells containing
BLM, but not in otherwise isogenic, BLM-deficient cells. We
discuss potential therapeutic uses of BLM-targeting compounds
derived from ML216 in the treatment of certain tumor types.
RESULTS
A High-Throughput Screen for Inhibitors of BLM
We developed a fluorescence-quenching assay (Figure S1
available online) to monitor DNA strand separation catalyzed
by BLM that was adapted for quantitative, high-throughput56 Chemistry & Biology 20, 55–62, January 24, 2013 ª2013 Elsevier Ltd All rights reservedscreening (qHTS) for inhibitors of BLM
(seeExperimental Procedures). Theassay
utilized a dual-labeled, partial duplex
DNA substrate (‘‘forked’’ duplex) in whichthe fluorescence of a rhodamine-type moiety is normally sup-
pressed by a nonemitting dark quencher (BHQ-2) present on
the opposite strand. This quenching is lost following the ATP-
dependent unwinding of the two DNA strands by the BLM heli-
case and hence a fluorescent signal is produced (Figures S1A
and S1B). This assay was miniaturized to a 1,536-well format
and used to screen the Molecular Libraries Small Molecule
Repository library of approximately 350,000 compounds (Fig-
ureS1C). The inhibitory activity of the compoundswasmonitored
as a diminution in the fluorescent signal compared to that from
the negative control sample containing DMSO alone. Dose-
response curves of potential BLM inhibitors from the primary
screen are shown in Table S1. Primary screening hits were
analyzed in a more traditional helicase assay, where separation
of a radiolabeled, forked duplex substrate into single-stranded
DNA (ssDNA) products is measured using PAGE. Of the screen-
ing hits that showed activity in both the fluorescence- and radio-
activity-based assays, compound MLS000559245 was selected
for further medicinal chemistry optimization directed primarily at
improving physicochemical properties such as solubility and cell
permeability. An optimized analog, ML216 (Figure 1A), emerged
as the lead molecule for the present study. Further details of
the optimization process will be published elsewhere.
ML216 Is a Potent Small Molecule Inhibitor of BLM
In the qHTS assay, we used a truncated variant of BLM that lacks
the N-terminal 635 residues and the C-terminal 119 residues
of BLM (hereafter called BLM636–1298) in order to meet the
requirement for milligram quantities of recombinant BLM in the
large-scale screen, which cannot be generated for the full-length
BLM protein. Although the truncated protein is fully functional
as a helicase, we wanted to confirm that ML216 is also able
to inhibit the activity of full length BLM, and to do so in a concen-
tration-dependent manner. We found that ML216 is a potent
inhibitor of both full-length BLM and BLM636–1298, showing
similar IC50 values of 3.0 and 0.97 mM, respectively (Figures 1B
and 1C; Table 1).
Table 1. Inhibition Selectivity of ML216 against Related
Helicases
Helicase IC50 (mM)
a 95% Confidence Interval
BLM636–1298 0.97 0.8–1.2
BLMfull-length 2.98 2.2–4.0
WRNshort 12.60 10.7–14.8
WRNlong 5.00 4.6–5.5
RecQ1 >50 NA
RecQ5 >50 NA
UvrD >50 NA
NA, not applicable.
aDetermined by gel-based DNA unwinding assay.
Figure 2. ML216 Affects the DNA Binding Activity of BLM
(A) Effect of ML216 on binding BLM to ssDNA or a forked duplex using EMSA.
Data were derived from two independent gel retardation experiments. Error
bars: SE.
(B) As in (A), except effects on DNA binding measured using fluorescence
polarization (FP). Measurements were performed in the absence of nucleotide
or in the presence of ADP or ATP, as indicated. Data were derived from three
independent experiments.
Error bars: SD. See also Figure S2.
Chemistry & Biology
Inhibitor of BLMBLM has a broad substrate range in addition to its ability to
unwind the forked duplex DNA used in the initial screen. Addi-
tional substrates include DNA displacement loops (D-loops),
Holliday junctions and G-quadruplexes (Bachrati et al., 2006;
Ellis et al., 1995; Mohaghegh et al., 2001; Sun et al., 1998). In
at least the case of the Holliday junction, BLM exerts its effect
on the DNA via promoting branch migration of the four-way
DNA junction, and not by catalyzing DNA strand separation.
Moreover, we have provided evidence previously that BLM
might disrupt the mobile D-loop substrate used here via migra-
tion of the three-way junction (Bachrati et al., 2006). We asked,
therefore, whether ML216 is able to inhibit BLM’s action on
a D-loop, a G-quadruplex, or a synthetic Holliday junction. We
found that ML216 could inhibit disruption of the D-loop and
Holliday junction substrates, although only at high concentra-
tions (50 mM) (Figures S1D and S1F). Moreover, only verymodest
inhibition of BLM’s G-quadruplex disrupting activity was
observed (Figure S1E). These data suggest that ML216 is
much more potent as an inhibitor of BLM’s strand separation
activity on a forked duplex substrate than it is as an inhibitor of
either branch migration of DNA junctions or G-quadruplex DNA
disruption.
Next, we asked whether ML216 could inhibit other human
RecQ family helicases, which are closely homologous to BLM
in their helicase domains. In parallel, we also tested a putative
negative control, Escherichia coli UvrD helicase, which is
a very distantly related enzyme belonging to helicase Super-
family I. ML216 showed only very modest inhibition of the
helicase activity of E. coli UvrD or human RECQ1 and RECQ5,
even at a concentration of 50 mM (Table 1). ML216 did, however,
show inhibition of the WRN helicase. ML216 inhibited both the
full length WRN and a truncated WRN derivative (WRN500-946),
with the former being 2.5-fold more sensitive to inhibition
(based on IC50 values). BLM was a little more sensitive than
WRN to inhibition by ML216 (1.7-fold based on IC50 values;
Table 1). Despite the detectable inhibition of WRN by ML216,
this compound appears selective for BLM in human cells, as
we discuss below.
Mechanism of Action of ML216
ML216 could, in principle, inhibit BLM via a variety of different
mechanisms such as by competing with ATP binding, the driving
force behind its DNA unwinding, or by preventing BLM from
binding to DNA. To investigate the mechanism of action ofChemistry & Biology 20,ML216, we analyzed its effects on DNA binding by BLM using
an electrophoretic mobility shift assay (EMSA). This analysis
provided clear evidence of displacement of either ssDNA or
forked duplex DNA from a complex with BLM with increasing
concentrations of ML216 (Figures 2A, S2A, and S2B). To confirm
this finding, fluorescence polarization analysis was undertaken,
where the binding of BLM to a fluorescently labeled oligodeoxy-
nucleotide corresponding to the upper strand of the forked
duplex substrate (Table S2; A1) was monitored in the presence
of a dilution series of ML216. This test also showed that
ML216 inhibits the ability of BLM to bind DNA (Figure 2B). Taken
together, these data strongly suggest that ML216 competes
with the DNA for binding to BLM.
BLM requires ssDNA binding for its ATPase activity. Con-
sistent with ML216 being able to disrupt BLM’s binding to
DNA, rather than being an inhibitor of ATP binding by BLM, the
inhibition of ssDNA-dependent ATPase activity by ML216 (Ki of
1.76 ± 0.26 mM) was noncompetitive with respect to ATP
(Figure S2C).55–62, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 57
Figure 3. ML216Has Activity in HumanCells
that Depends on BLM
(A and B) Effects of different concentrations of
ML216, as indicated, on the rate of cell prolifera-
tion in PSNF5 (BLM+; A) and PSNG13 (BLM; B)
cells. Data represent the means of three inde-
pendent experiments. Error bars: SD. **p < 0.01;
*p < 0.05.
(C and D) Effects of ML216 on SCE levels. PSNF5
or PSNG13 cells were untreated or treated with
ML216, as indicated below the bars, and the
frequency of SCEs per chromosome (C) and the
number of SCEs per chromosome (D) were
determined.
See also Figure S3.
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Inhibitor of BLMML216 Is Active in Cultured Human Cells
ForML216 to be an inhibitor with broad utility, it would have to be
cell membrane permeable and capable of inhibiting the function
of BLM in living cells. To investigate this, we compared the
effects of ML216 in two cell lines that were derived from
GM08505, a fibroblast cell line isolated from a patient with BS.
One cell line, PSNG13, has been transfected with an empty
vector alone, and therefore lacks BLM. The other, PSNF5, is
isogenic to PSNG13, but has been transfected with the BLM
cDNA. Previous studies showed that such re-expression of
BLM in the PSNF5 cells corrects the hyper-SCE phenotype of
the parental GM08505 cells (Gaymes et al., 2002). Using this
isogenic pair of cells, we sought to identify whether ML216 could
influence cell growth and SCE induction in a BLM-specific
manner. We found that ML216 was an inhibitor of the prolifera-
tion of PSNF5 cells, but not of PSNG13 cells, and did so in
a concentration-dependent manner (Figures 3A and 3B). More-
over, ML216 treatment led to a statistically significant increase
in the frequency of sister chromatid exchanges (SCEs) in
PSNF5 cells, but not in PSNG13 cells (Figures 3C and 3D).
In each experiment conducted thus far, the exposure time of
cells to ML216 was 24–72 hr. However, for ML216 to have broad
utility in cellular studies, it would ideally have to inhibit BLM
during only a short treatment period. Hence, we asked whether
ML216 could induce SCEs in PSNF5 cells if present only during
the last 8 hr of the experiment prior to collection of cells in
metaphase. That way, BLM would be targeted by ML216 only
during the second S-phase of exposure to bromodeoxyuridine
(BrdU), because SCE analysis requires that BrdU be present58 Chemistry & Biology 20, 55–62, January 24, 2013 ª2013 Elsevier Ltd All rights reservedduring two consecutive S-phases before
cells are arrested with colcemid and
metaphases are harvested. We found
that this shorter exposure led to a statisti-
cally significant increase in the frequency
of SCEs in PSNF5 cells expressing BLM
(Figure S3A).
PSNG13 cells are hypersensitive
compared to PSNF5 cells to inhibitors of
DNA replication, such as aphidicolin, an
inhibitor of replicative DNA polymerases
(Davies et al., 2004). We asked, therefore,
whether ML216 might selectively sensi-
tize PSNF5 cells to aphidicolin, presum-ably by inhibiting BLM. As shown in Figure 4A, ML216 increased
the sensitivity of PSNF5 cells to aphidicolin (p < 0.01) but had no
sensitizing effect on isogenic PSNG13 cells devoid of BLM.
Previous studies (Chu et al., 2010) using mouse embryonic
stem (ES) cells have indicated that BLM is required to convert
mitomycin-C-induced DNA damage (likely DNA interstrand
crosslinks) into double-strand breaks (DSBs), which can be de-
tected by immunofluorescent staining of cells for the phosphor-
ylated version of histone H2AX (termed g-H2AX). We found that
PSNF5 cells showed a substantially higher frequency of g-H2AX
nuclear foci in response to mitomycin C (MMC) exposure than
did PSNG13 cells, in agreement with the previous study of
mouse ES cells (Chu et al., 2010). Consistent with ML216 target-
ing BLM in living cells, we observed a statistically significant
reduction in g-H2AX focus formation in PSNF5 cells treated
with the combination of ML216 and MMC compared to PSNF5
cells treated with MMC alone (Figures 4B and S3B; p < 0.05).
As expected, ML216 showed no significant effect on the control
PSNG13 cells, with or without MMC treatment (Figures 4B and
S3B; p > 0.05) because these cells display no g-H2AX foci
following this MMC treatment regimen.
The cellular data presented thus far indicate that ML216 can
target BLM in human cells, but do not rule out the possibility
that it also targets WRN, given that WRN protein is inhibited by
ML216 in vitro. To investigate this, we tested whether fibroblasts
lacking WRN were differentially sensitive to ML216 compared to
wild-type control fibroblasts. We found that ML216 inhibited
proliferation of WRN+ and WRN cells equally well, and similarly
sensitized both cell types to aphidicolin (Figure S4). Taken
Figure 4. ML216 Affects the Cellular
Response to DNA Damage Stress in
a BLM-Dependent Manner
(A) ML216 sensitizes PSNF5, but not PSNG13,
cells to aphidicolin. Survival curves derived from
clonogenic assays are shown from each cell line in
the absence or presence of ML216. Cells were
exposed toML216 for 24 hr before aphidicolin was
added at the concentrations indicated and the
cells were incubated for a further 24 hr. Cells were
then washed and incubated in drug-free medium
for up to 12 days to allow individual colonies to
form. Points represent the average of three inde-
pendent experiments. Error bars: SD.
(B) ML216 suppresses g-H2AX focus formation in
MMC-treated PSNF5 cells, but not similarly
treated PSNG13 cells. Integrated fluorescence
density on a minimum of 75 cells in each case was
determined using ImageJ software (NIH).
See also Figure S4.
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Inhibitor of BLMtogether, these data indicate that ML216 can specifically inhibit
the function of BLM in human cells.
DISCUSSION
In this study, we report the identification and characterization of
a small molecule inhibitor of the human BLM helicase. This
compound, designated ML216, resulted from medicinal chem-
istry-based optimization of compound MLS000559245, which
was identified via high throughput screen of a library of ‘‘drug-
like’’ molecules. Based on our analysis of ML216 in human cell
lines, we conclude that the compound is membrane permeable
and can target BLM in living cells. The general lack of any effects
of ML216 on a BS cell line, which does not express BLM, is
strongly suggestive that the primary target for ML216 in human
cells is BLM.
The initial screen was conducted using a truncated variant of
BLM, BLM636-1298, which was prepared from bacteria. Neverthe-
less, we confirmed that full-length recombinant BLM (isolated
from yeast cells) was inhibited to a similar degree based on
IC50 values. This strongly suggests that ML216 targets the
central ‘‘catalytic core’’ of BLM contained in both recombinant
BLM preparations comprising the helicase, RQC, and HRDC
domains. Given the strong selectivity of ML216 for BLM
compared to human RECQ1 and RECQ5, we believe that it
must target a structural feature of BLM that is poorly conserved,
even among many human RecQ family helicases. Although the
inhibition of WRN seen in helicase assays indicates that ML216
can target this closely related helicase (albeit, with a somewhat
lower potency), the cell-based assay results probing many
different functions of BLM indicate strongly that ML216 does
not interfere significantly with WRN function in vivo. Despite
this contention, it is still possible that ML216 targetsWRN in vivo,
yet does not have any effect on the cellular endpoints analyzed
here, including proliferation and aphidicolin sensitivity. However,
the inhibition of WRN did also potentially reveal an interesting
feature of the mode of action of ML216. We found that a trun-
cated (but catalytically active) WRN was inhibited weakly by
ML216, while full length WRN was more sensitive. In contrast,
both truncated BLM (residues 636–1298) and full length BLMChemistry & Biology 20,were inhibited with similar IC50 values. Given that the truncated
WRN retains the helicase domain, these data suggest that resi-
dues outside of the helicase core of WRN might participate in
DNA binding/unwinding and be targeted by ML216. A likely
candidate is the RQC domain. Unfortunately, we currently only
have access to the high resolution structure of human RECQ1
(Pike et al., 2009), and not of BLM, WRN, or RECQ5, and there-
fore more detailed analysis of the binding region for ML216 on
BLM will have to await new structural studies.
We have providedmechanistic insight into howML216 targets
BLM.ML216 could inhibit the DNA-dependent ATPase activity of
BLM, but did so in a noncompetitive manner with respect to ATP.
The use of both gel retardation and fluorescence polarization
assays revealed that ML216 inhibits DNA binding by BLM, which
would be sufficient to block its helicase activity. DNA binding,
particularly of partial duplex DNA structures such as the forked
duplex studied extensively here, seems to require both the
helicase and RQC domains of RecQ helicases (Pike et al.,
2009). Moreover, the HRDC domain is known to influence DNA
substrate specificity of BLM by altering its affinity for different
DNA structures (Wu et al., 2005). ML216 showed preferential
inhibition of the unwinding of a forked duplex by BLM. Its ability
to inhibit disruption of D-loops, three-/four-way junctions, and
G-quadruplexes required approximately 10-fold higher drug
concentrations. This pronounced DNA substrate-structure
dependency of inhibition, combined with the EMSA and fluores-
cence polarization studies, argue strongly for a selective
engagement of ML216 into the BLM-nucleic acid substrate
binding site.
During the cellular analyses of the effects of ML216, we
analyzed whether this compound, through targeting BLM, might
activate cell-cycle checkpoint responses. However, we obtained
no evidence to suggest that ML216 did so. Exposure of cells for
24 hr to 50 mM ML216 did not cause cell-cycle arrest in G1/S or
G2/M, and did not appear to cause phosphorylation of well-
established ATM or ATR targets, including CHK1 and CHK2
(data not shown). This is consistent with a lack of requirement
for BLM to activate these checkpoints in human cells.
We have presented evidence thatML216modulates the role of
BLM in genomemaintenance in human cells. The most revealing55–62, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 59
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Inhibitor of BLMphenotypic effect of ML216 treatment of cells was an increase in
the frequency of SCEs. Crucially, this induction of SCEs was
seen only in cells expressing BLM and not in otherwise isogenic
cells lacking BLM. Given the importance of BLM in suppression
of SCEs in human cells (Chaganti et al., 1974; Chu and Hickson,
2009), this increase in SCE argues strongly for on-target effects
of ML216. An interesting feature of the action of ML216 is its
ability to partially inhibit proliferation of cells expressing BLM
but not those lacking BLM. It is clear from analysis of cell lines
isolated from BS patients that BLM is not an essential gene in
humans (unlike in mice) (Chester et al., 1998). Nevertheless, as
has been observed in numerous other cases, acute inactivation
of enzyme function often has more deleterious effects than does
removing the protein altogether. This may be due to secondary
effects on protein complexes in which the target protein partici-
pates. Our in vitro biochemical data indicated that ML216 could
inhibit WRN nearly as efficiently as it does BLM. Nevertheless,
our cellular studies using cell lines lacking either BLM or WRN
indicated that the effects of ML216 on cell proliferation, aphidi-
colin sensitivity, and SCE induction were consistent with BLM
being the primary target of the compound, and not WRN.
Very recently, Aggarwal et al. (2011) characterized a set of
small molecule inhibitors of WRN. The compound analyzed in
most detail in that study (NSC 19630) was highly toxic to human
cells in culture at low micromolar concentrations. We currently
do not know why we did not see any antiproliferative effects
of ML216 on cells lacking BLM, even though ML216 inhibits
WRN with a similar potency to that of NSC 19630. Of note,
NSC 19630 is a maleimide derivative and therefore likely to be
chemically reactive to the free cysteine thiol groups present on
several proteins, as well as on nonprotein cellular components,
such as intracellular glutathione, a recognized mediator of
cellular response to oxidative stress. It is possible, therefore,
that these effects combined could conspire to produce the
toxicity observed with NSC 19630.
SIGNIFICANCE
Wehave identified a smallmolecule inhibitor of theBLMheli-
case, the protein defective in the cancer predisposition
disorder, Bloom’s syndrome. This inhibitor, ML216, is cell
membrane permeable and appears to be highly specific for
inhibition of BLM in human cells. We suggest that ML216
is a suitable ‘‘molecular probe’’ for detailed analysis of the
role of BLM in the maintenance of genome stability,
including the identification of factors that are required to
compensate for the loss of BLM function. A major future
use of BLM-targeting compounds lies in the testing of the
hypothesis that tumor cells that depend on the so-called
ALT (alternative lengthening of telomeres) mechanism for
maintenance of chromosome ends (telomeres), rather than
on telomerase, might be susceptible to BLM inhibition.
Work in yeast has revealed that the BLM ortholog, Sgs1, is
required for telomere maintenance in the absence of telo-
merase, at least under certain circumstances (Cohen and
Sinclair, 2001; Huang et al., 2001; Johnson et al., 2001). More-
over, depletion of the BLM partner protein, Topoisomerase
IIIa, from human ALT cells strongly inhibits proliferation
(Temime-Smaali et al., 2008). The availability of ML216 now60 Chemistry & Biology 20, 55–62, January 24, 2013 ª2013 Elsevierallows the testing of BLM inactivation in ALT cells. A
successful proof of principle would open up the potential
for analogs of ML216, or newly developed BLM inhibitors,
to be used clinically to target the 5%–10% of tumors that
depend for their continued proliferation on the ALT pathway.
Given that several of the ALT tumor types, such as osteosar-
comas, are refractory to conventional treatments, this could
open up a new therapeutic strategy for targeting these treat-
ment-resistant tumors.
EXPERIMENTAL PROCEDURES
Proteins and Oligonucleotides
Recombinant human BLM, WRN, and RECQ1 helicases were expressed and
purified to near homogeneity as described previously (Mohaghegh et al., 2001;
Popuri et al., 2008). E. coli UvrD, the human RECQ5, and truncated WRN
(residues 500–946 fused toGST) helicaseswere obtained fromDrs. S.Matson,
P. Janscak, and R. Brosh, respectively. Oligonucleotides were synthesized
by Sigma-Aldrich (Haverhill, UK), Biosearch Technologies (Novato, CA), and
the oligonucleotide synthesis service of Cancer Research UK (CRUK) (see
Table S2 for sequences).
BLM High-Throughput Screening Assay
The high-throughput screening for inhibitors of BLM activity was conducted
using a forked duplex DNA substrate, which harbored a tetramethylrhodamine
fluorophore at the 30 end of one strand (Table S2; A1) and a nonfluorescent,
Black Hole Quencher-2 at the 50 end of the complementary strand (Table
S2; A2). An increase in the fluorescence intensity as a result of the ATP-depen-
dent unwinding of the duplex region by BLM was used to measure helicase
activity. For details, see Supplemental Experimental Procedures.
Preparation of Radiolabeled Substrates
For each substrate, a single oligonucleotide was 50 end labeled with [g-32P]
ATP using T4 polynucleotide kinase. The forked duplex, X12 four-way junction
(Holliday junction), D-loop, and G4 DNA substrates were generated as des-
cribed previously (Bachrati et al., 2006; Mohaghegh et al., 2001; Sun et al.,
1998; van Brabant et al., 2000). Prior to use, each substrate was gel-purified
and dialyzed against the buffers described in Supplemental Experimental
Procedures. The concentration of the labeled substrate was determined using
scintillation counting. For details, see Supplemental Experimental Procedures.
DNA Helicase Activity Measured by Gel Electrophoresis of
Radiolabeled DNA
Helicase assays were carried out in a 100 ml reaction volume containing no
more than 1%DMSO, with the inhibitors being added in a 1 ml volume. Results
were expressed as percent unwinding normalized to the untreated (taken as
0%) and denatured DNA (100%) control samples. Enzyme concentrations
required for 50% substrate unwinding, and inhibitor concentrations required
for 50% enzyme inhibition (IC50 values) were determined using a nonlinear
regression model using GraphPad software. For detailed information, see
Supplemental Experimental Procedures.
DNA Helicase Activity Measured by Gel Electrophoresis of
Fluorescently Labeled DNA
The forked duplex substrate was prepared by annealing the 30-TAMRA-
labeled A1 oligonucleotide (Table S2) with the unlabeled complementary
strand, A2 (Table S2). A standard 20 ml reaction contained 50 mM Tris-HCl
(pH 7.5), 50 mM NaCl, 2 mM MgCl2, 2 mM ATP, 1 mM DTT, 0.1% Tween-20,
and 200 nM TAMRA-labeled forked duplex substrate. Following electropho-
resis, DNA was visualized using the Bio-Rad ChemiDocTM XRS Gel Imager.
Fluorescence Polarization Assays
Equilibrium binding of DNA helicases to TAMRA-labeled oligonucleotides was
monitored by fluorescence polarization. Serial dilutions of selected inhibitors
were mixed with the indicated amounts of DNA helicase and the TAMRA-
labeled oligonucleotide (Table S2; A1). Following incubation at roomLtd All rights reserved
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Inhibitor of BLMtemperature for2 hr, plates were read on a ViewLux high-throughput CCD
imager. For a detailed protocol, see Supplemental Experimental Procedures.
Cell Lines
GM08505 is an SV40-transformed skin fibroblast cell line established from
a patient with BS. PSNF5 is a stable transfectant of GM08505 expressing
Flag epitope-tagged BLM protein, while PSNG13 is an empty vector control
transfectant of the same cell line. These transfected clones have been
described previously (Gaymes et al., 2002). GM00637 and AG11395 are
SV40-transformed fibroblasts from a normal individual and a patient with
WS, respectively. Details of culture conditions for these lines are provided in
Supplemental Experimental Procedures.
Proliferation Assays
Cells were treated with BLM inhibitors at the indicated concentrations for up
to 72 hr. At each time point, the WST-1 reagent (a pale tetrazolium derivative
converted to an intensely colored formazan product by the action of mito-
chondrial dehydrogenases) was added, and after a 4 hr incubation the plates
were analyzed optically at 450 nm with a reference wavelength of 690 nm.
For details, see Supplemental Experimental Procedures.
Clonogenic Survival and SCE Analysis
Clonogenic survival assays and SCE analysis were performed as described
previously (Davies et al., 2004).
Fluorescence Microscopy
PSNG13 and PSNF5 cells were treated with either DMSO or ML216 at the
concentrations described for 48 hr before exposure to mitomycin C for a
further 12 hr. Cells were then fixed and permeabilized using 4% paraformalde-
hyde and ice-cold 70% ethanol. Fixed cells were stained with a primary anti-
body for g-H2AX (Upstate anti-mouse; 05-636). DAPI staining was used to
define the location of cell nuclei.
Chemical Synthesis of ML216
Synthetic schemes and protocols describing the preparation of ML216 and
other compounds, as well as supporting analytical data, are provided in
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.chembiol.2012.10.016.
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